Bone Mineral Density News and Research

RSS

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

Experts at Ninth International Symposium discuss health effects and safety of S-equol

The latest research into the health effects and safety of a soy-based compound called S-equol was described in talks and presentations by experts at a special session on Tuesday, Oct. 19 during the Ninth International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment, held Oct. 16 to 19 in Washington, D.C.

20 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Women with normal bone mineral density at age 67 don't need osteoporosis screening again for 10 years

Since 2002, the U.S. Preventive Services Task Force has recommended that women ages 65 and older be routinely screened for osteoporosis and has suggested that a 2-year screening interval might be appropriate. However, what length the screening interval should be is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

New 2010 clinical practice guidelines for diagnosis and management of osteoporosis in Canada released

Today, Osteoporosis Canada released its 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada, published in the Canadian Medical Association Journal. The new guidelines represent a paradigm shift in the prevention and treatment of osteoporotic fractures, moving the focus from treating low bone mineral density (BMD) to better identifying fractures caused by weakened bones (fragility fractures).

12 Oct 2010

Tips to keep bones strong

October 20 is World Osteoporosis Day. Most people know that osteoporosis is a condition that affects many older women. Though osteoporosis isn't as common in men -- because most men have naturally larger and stronger bones -- they can get it, too.

11 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

$LIPUS ultrasound can speed fracture healing$

LIPUS ultrasound can speed fracture healing

Ultrasound can speed the healing of fractures. A randomized controlled trial reported in the open access journal BMC Musculoskeletal Disorders has found that the use of low-intensity pulsed ultrasound (LIPUS) in patients with tibial fractures which showed inadequate progress toward healing resulted in 34% greater bone mineral density (BMD) in the fracture area after 16 weeks than use of a sham device.

8 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

Vitamin D supplementation in healthy kids pointless: Study

According to a Cochrane Systematic Review released on October 6th, yesterday vitamin D supplements when given to healthy children with normal vitamin D levels does not improve bone density at the hip, lumbar spine, forearm or in the body as a whole.

6 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Bone Mineral Density News and Research

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Experts at Ninth International Symposium discuss health effects and safety of S-equol

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Women with normal bone mineral density at age 67 don't need osteoporosis screening again for 10 years

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Acceleron announces ACE-031 Phase 1b study results

New 2010 clinical practice guidelines for diagnosis and management of osteoporosis in Canada released

Tips to keep bones strong

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

LIPUS ultrasound can speed fracture healing

Soy germ-based nutritional supplement helps to manage menopausal symptoms

Vitamin D supplementation in healthy kids pointless: Study

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News